Edition:
United States

Perrigo Company PLC (PRGO.N)

PRGO.N on New York Stock Exchange

69.57USD
12:21pm EDT
Change (% chg)

$-0.07 (-0.10%)
Prev Close
$69.64
Open
$69.43
Day's High
$69.72
Day's Low
$68.69
Volume
109,967
Avg. Vol
317,550
52-wk High
$95.82
52-wk Low
$67.55

Chart for

About

Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company's segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. It manufactures OTC healthcare... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $9,678.50
Shares Outstanding(Mil.): 138.46
Dividend: 0.19
Yield (%): 1.09

Financials

  PRGO.N Industry Sector
P/E (TTM): 39.35 28.53 31.56
EPS (TTM): 1.77 -- --
ROI: 2.52 13.22 12.88
ROE: 4.17 15.20 15.04

UPDATE 2-AbbVie, AndroGel partner owe $448 million in antitrust case -U.S. judge

June 29 A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from getting to market and ordered the drugmaker and its partner to pay $448 million.

Jun 29 2018

BRIEF-Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg

* ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES

May 16 2018

BRIEF-Perrigo Says Terminated Existing Credit Agreements

* PERRIGO - EFFECTIVE MARCH 8, CO TERMINATED EXISTING CREDIT AGREEMENTS & REPLACED THEM WITH A NEW SENIOR UNSECURED REVOLVING AND TERM LOAN CREDIT AGREEMENT

Mar 09 2018

BRIEF-Perrigo - John Hendrickson's 2017 Total Compensation $8.3 Million Versus $5.8 Million In 2016

* PERRIGO COMPANY PLC CEO JOHN HENDRICKSON'S 2017 TOTAL COMPENSATION $8.3 MILLION VERSUS $5.8 MILLION IN 2016 - SEC FILING

Mar 09 2018

BRIEF-Perrigo CEO Buys 7,500 Shares Of Co's Ordinary Shares On March 5

* PERRIGO CEO UWE ROEHRHOFF REPORTS PURCHASE OF 7,500 SHARES OF CO'S ORDINARY SHARES ON MARCH 5 - SEC FILING Source text: (http://bit.ly/2Fpn04Z) Further company coverage:

Mar 07 2018

BRIEF-Perrigo Announces Final FDA Approval And Planned Launch For The Store Brand OTC Equivalent Of Mucinex DM Maximum Strength Extended Release Tablets

* PERRIGO ANNOUNCES FINAL FDA APPROVAL AND PLANNED LAUNCH FOR THE STORE BRAND OTC EQUIVALENT OF MUCINEX® DM MAXIMUM STRENGTH EXTENDED RELEASE TABLETS

Mar 07 2018

BRIEF-Perrigo Company Q4 GAAP Earnings Per Share $0.52

* REPORTS FOURTH QUARTER & CALENDAR YEAR 2017 FINANCIAL RESULTS

Mar 01 2018

BRIEF-Perrigo Company Reports Select Preliminary Unaudited 2017 Financial Results

* REPORTS SELECT PRELIMINARY UNAUDITED CALENDAR YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Perrigo Confirms Patent Challenge For Generic Version Of Finacea Foam, 15%

* PERRIGO CONFIRMS PATENT CHALLENGE FOR GENERIC VERSION OF FINACEA® FOAM, 15%

Feb 20 2018

BRIEF-Perrigo Appoints Ronald Winowiecki As CFO

* PERRIGO APPOINTS RONALD L. WINOWIECKI AS CHIEF FINANCIAL OFFICER

Feb 20 2018

Earnings vs. Estimates